Probiotic Applications in Inflammatory Bowel Disease

Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, arises from complex interactions between genetic predisposition, environmental triggers and immune dysregulation. Central to its pathogenesis is a perturbation of the gut microbiota, or dysbiosis, which compromises mucosal barrier integrity and amplifies inflammatory cascades. Probiotics—live microorganisms that confer health benefits when administered in adequate amounts—have been investigated as adjunctive therapies to restore microbial equilibrium and modulate host immunity. Studies in preclinical models and clinical trials have demonstrated that selected bacterial strains can enhance mucus production, strengthen tight junctions, regulate cytokine profiles and produce short-chain fatty acids (SCFAs) that foster intestinal homeostasis. Delivery vehicles such as fermented dairy matrices have further been shown to protect probiotic viability and amplify anti-inflammatory effects. Taken together, probiotic applications hold promise for personalised management of IBD by targeting key microbial and immunological pathways.

Research from Nature Portfolio

Recent studies have dissected the molecular basis of immunomodulation by dairy Propionibacterium freudenreichii. Comparative multi-strain analyses of surface and cytoplasmic proteins identified combinations of SLH-domain-containing surface-layer proteins (notably SlpB and SlpE) and a cytoplasmic methylation enzyme (HsdM3) that together induce anti-inflammatory IL-10 production by leukocytes, revealing that strain-specific protein repertoires underpin probiotic efficacy. In a complementary in vivo investigation, administration of P. freudenreichii or its culture supernatant in a rat model of dextran sodium sulphate (DSS)-induced colitis restored goblet cell numbers and upregulated the key mucus component MUC2. This treatment lowered disease activity indices, suppressed pro-inflammatory cytokines and increased faecal propionate levels, thereby reinforcing barrier function and attenuating acute colitis.

Probiotic Applications in Inflammatory Bowel Disease publication trend

The graph below shows the total number of articles in probiotic applications in inflammatory bowel disease across all publications each year (not limited to Nature Index journals).

Technical terms

Inflammatory bowel disease (IBD): A group of chronic disorders characterised by gastrointestinal tract inflammation, chiefly ulcerative colitis and Crohn’s disease.

Probiotics: Live microorganisms which, when administered in adequate amounts, confer a health benefit on the host.

Dysbiosis: An imbalance in the composition or function of the gut microbiota associated with disease pathogenesis.

Dextran sodium sulphate (DSS) model: A chemical method to induce colitis in rodents, widely used to simulate aspects of human IBD.

Mucin MUC2: The principal gel-forming protein secreted by goblet cells that constitutes the protective mucus barrier in the colon.

Cytokines: Small signalling proteins released by cells, especially of the immune system, to regulate inflammation and immunity.

Surface-layer proteins (SLPs): Cell-enveloped proteins that mediate adhesion to host cells and interact with immune receptors to modulate host responses.

References

1. Identification of proteins involved in the anti-inflammatory properties of Propionibacterium freudenreichii by means of a multi-strain study. Scientific Reports (2017).
2. Dairy Propionibacterium freudenreichii ameliorates acute colitis by stimulating MUC2 expression in intestinal goblet cell in a DSS-induced colitis rat model. Scientific Reports (2020).
3. Fat matters: Fermented whole milk potentiates the anti-colitis effect of Propionibacterium freudenreichii. Journal of Functional Foods (2023).
4. Therapeutic Effects of Probiotic Minas Frescal Cheese on the Attenuation of Ulcerative Colitis in a Murine Model. Frontiers in Microbiology (2021).